Adaptive Biotechnologies
ADPT
219 hedge funds and large institutions have $4B invested in Adaptive Biotechnologies in 2021 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 84 increasing their positions, 63 reducing their positions, and 29 closing their positions.
58% more call options, than puts
Call options by funds: $6.5M | Put options by funds: $4.11M
33% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 63
0.05% more ownership
Funds ownership: 83.68% → 83.73% (+0.05%)
5% less funds holding
Funds holding: 230 → 219 (-11)
16% less capital invested
Capital invested by funds: $4.8B → $4B (-$791M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
24% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.4M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$17.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.3M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$13.5M |
| 5 |
BlackRock
New York
|
+$9.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$50.7M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$26.6M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$15.8M |
| 4 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$8.23M |
| 5 |
ZCI
Zevenbergen Capital Investments
Edmonds,
Washington
|
-$8.04M |
ADPT Hedge Fund Activity: Q3 2021 in Review
219 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q3 2021, worth a combined $4B — down 16% from $4.8B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ADPT and 22 opened new positions — a net loss of 7 holders — while 63 trimmed existing stakes and 84 added.
The largest buyer was Vanguard Group, adding an estimated $29.4M. The largest seller was SB Management, exiting entirely with an estimated $50.7M sold.
- 219 institutional investors held Adaptive Biotechnologies (ADPT) as of Q3 2021, down from 230 in Q2 2021.
- Funds reported $4B of Adaptive Biotechnologies stock for Q3 2021, down 16% quarter-over-quarter.
- 22 funds opened new Adaptive Biotechnologies positions in Q3 2021 and 29 closed out, a net change of -7 holders.
- The largest Adaptive Biotechnologies buyer in Q3 2021 was Vanguard Group, an estimated $29.4M added.
- The largest Adaptive Biotechnologies seller in Q3 2021 was SB Management, an estimated $50.7M sold.
Based on aggregated 13F filings for Q3 2021.